The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

• Status: Not yet recruiting
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomized controlled pilot study on the safety & efficacy of imatinib for the treatment of patient with moderate to severe SARS-COV-2 induced pneumonia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexandria University
• Collaborator: Science, Technology & Innovation Funding Authority (STIFA), Egypt
• Treatments: Imatinib Mesylate

Criteria

Inclusion Criteria:

• Patients with PCR positive for SARS-COV-2

• Hospitalized with moderate to severe respiratory symptoms as assessed by the Egyptian Ministry of Health National Guidelines

• Informed consent explained & signed by patient or his 1st degree relatives or legally authorized representative.

Exclusion Criteria:

• Pregnant women (or) breast feeding women

• Patients younger than 18 years of age

• Patients with known allergy to imatinib

• Total bilirubin, aspartate aminotransferase (AST), or alanine aminotransferase (ALT) > 5x upper limit of normal (ULN).

• Creatinine clearance (CrCl) < 30 mL/minute.

• Patient already on mechanical ventilation at time of screening.